top of page
Sorting Medicine
Reach Pharmaceuticals
Providing Emerging Therapeutics Globally 

> Latest Company News

May 2024: The TGA approved an alternative to the permethrin 5% w/w cream product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until October 31, 2024. Contact Us for more details.

April 2024: The TGA approved an alternative to the XYLOCAINE 2% with Epinephrine 1:200,000 20ml ampoule product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until September 30, 2024. Contact Us for more details.

April 2024: The TGA approved an alternative to the 25 micrograms/24 hours estradiol transdermal patches product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until October 31, 2024. Contact Us for more details.

April 2024: NELARABINE-REACH is now approved in Australia and is available at all wholesalers. Contact Us for more

details.

December 2023: The TGA approved an alternative to the XYLOCAINE 2% with Epinephrine 1:200,000 20ml ampoule product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until April 30, 2024. Contact Us for more details.

December 2023: The TGA approved an alternative to the amidotrizoate meglumine, sodium amidotrizoate oral solution product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until April 30, 2024. Contact Us for more details.

December 2023: ROMIDEPSIN-REACH 10 mg for injection is now available at all wholesalers. Contact Us for more details.

December 2023: NELARABINE-REACH 250 mg/50 mL for injection is now available under S19A of the Therapeutic Goods Act, 1989 until April 30, 2024. Contact Us for more details.

bottom of page